- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:18 | Marvel Biosciences Corp: Marvel gains Australian patent allowance for MB-204 | 1 | Stockwatch | ||
| 13:06 | Marvel Biosciences Corp.: Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204 | 68 | GlobeNewswire (Europe) | CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 20.05. | Marvel Biosciences Corp: Marvel Biosciences grants 50,001 DSUs to 3 directors | 1 | Stockwatch | ||
| 20.05. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 208 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 20, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 30.04. | Marvel Biosciences Corp: Marvel Biosciences $500,000 debenture private placement | 3 | Stockwatch | ||
| 23.04. | Marvel Biosciences Corp.: Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit | 1 | GlobeNewswire (USA) | ||
| 17.04. | Marvel Biosciences Corp: Marvel Biosciences closes $500,000 debenture offering | 2 | Stockwatch | ||
| 17.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Convertible Debenture Offering | 719 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced... ► Artikel lesen | |
| 16.04. | Marvel Biosciences Corp: Marvel Biosciences develops MB-204 liquid formulations | 3 | Stockwatch | ||
| 16.04. | Marvel Biosciences advancing autism drug for children | 1 | The Market Online Canada | ||
| 16.04. | Marvel Biosciences Corp.: Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders | 171 | GlobeNewswire (Europe) | CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company")... ► Artikel lesen | |
| 14.04. | Marvel Biosciences Corp: Marvel Biosciences amends debenture conversion price | 1 | Stockwatch | ||
| 13.04. | Marvel Biosciences lowers conversion price for proposed debenture offering | 1 | Seeking Alpha | ||
| 13.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering | 431 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention... ► Artikel lesen | |
| 08.04. | Marvel Biosciences plans convertible debenture private placement | 3 | Seeking Alpha | ||
| 08.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces Proposed Convertible Debenture Offering | 449 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement... ► Artikel lesen | |
| 07.04. | Marvel Biosciences Corp: Marvel Biosciences gets backing from 5 Horizons | 5 | Stockwatch | ||
| 07.04. | Marvel Biosciences Corp.: Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures | 394 | GlobeNewswire (Europe) | CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company")... ► Artikel lesen | |
| 30.03. | Marvel Biosciences Corp: Marvel obtains Alberta funding for MB-204 phase I | 1 | Stockwatch | ||
| 30.03. | Marvel Biosciences Corp.: Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204 | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 29,010 | +43,47 % | Tango Therapeutics: Aktie schießt nach beeindruckenden Studiendaten um über 30 % in die Höhe | ||
| NURIX THERAPEUTICS | 15,600 | +6,56 % | Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein | DJ Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein
Von Nina Kienle
DOW JONES--Roche hat mit dem US-Biotechunternehmen Nurix Therapeutics eine exklusive Lizenz- und Kooperationsvereinbarung... ► Artikel lesen | |
| QIAGEN | 31,805 | -2,53 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 84,24 | -3,08 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| PRAXIS PRECISION MEDICINES | 250,83 | -1,25 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| ERASCA | 12,800 | +6,93 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,460 | -2,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| BIONTECH | 75,85 | -2,88 % | BioNTech mit neuen Daten - doch reicht das? | BioNTech und der Partner Bristol Myers Squibb haben am Wochenende auf dem ASCO-Meeting in Chicago neue Zwischenergebnisse der Phase-2/3-Studie ROSETTA-Lung-02 veröffentlicht. Untersucht wird dabei der... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,120 | -2,41 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| SHATTUCK LABS | 3,815 | -16,70 % | Shattuck Labs, Inc.: Shattuck Labs Announces Phase 1 Results for SL-325 | Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,590 | +1,84 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,365 | +1,51 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,700 | +1,02 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,610 | -2,52 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,005 | +3,59 % | Relay Therapeutics Shares Jump 18% |
Das Unternehmen MARVEL BIOSCIENCES CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.